Introduction

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (hGH 177-191). Developed as an analog of the lipolytic domain of hGH, AOD-9604 was designed to retain the fat-reducing properties of growth hormone without its diabetogenic or growth-promoting effects. This case study examines the translational journey of AOD-9604 from molecular design through clinical evaluation.

Molecular Design Rationale

The hGH molecule (191 amino acids) contains multiple functional domains. Dr. Frank Ng and colleagues at Monash University identified the 177-191 fragment as the minimal sequence retaining lipolytic activity. AOD-9604 incorporates a tyrosine-to-alanine substitution at the C-terminus to enhance stability and prevent dimerization, while preserving the β-sheet conformation critical for receptor interaction. The peptide does not bind to the growth hormone receptor (GHR) but instead interacts with a putative lipolytic receptor enriched in adipose tissue.

Mechanism of Action

AOD-9604 stimulates lipolysis through β3-adrenergic receptor-mediated activation of hormone-sensitive lipase (HSL) in white adipose tissue. Unlike intact hGH, AOD-9604 does not elevate circulating IGF-1, insulin, or blood glucose levels. In vitro studies demonstrate a 60-80% increase in glycerol release from 3T3-L1 adipocytes treated with AOD-9604 compared to vehicle control, confirming direct lipolytic activity independent of the GHR-IGF-1 axis. Preclinical models in Zucker fatty rats showed a 50% reduction in body weight gain with preserved lean mass, distinguishing AOD-9604 from calorie-restriction approaches.

Clinical Development and Findings

Phase 2b clinical trials evaluated AOD-9604 in over 300 obese subjects with once-daily subcutaneous dosing at 1-2 mg for 12 weeks. The treatment group showed a statistically significant 2.6 kg greater weight loss compared to placebo (p<0.05) with a favorable safety profile. Importantly, no adverse effects on insulin sensitivity or glycemic control were observed, validating the fragment peptide approach to selective pharmacology. Subsequent Phase 3 trials were discontinued due to strategic portfolio decisions rather than safety concerns.

Current Research Applications

Contemporary research interest in AOD-9604 has expanded beyond obesity to include osteoarthritis management, where its chondroprotective effects have been demonstrated in preclinical cartilage degradation models. The peptide's ability to modulate cartilage oligomeric matrix protein (COMP) levels suggests potential application in degenerative joint disease. Additionally, AOD-9604 serves as a model system for fragment-based peptide drug design, illustrating how bioactive protein domains can be isolated and optimized for therapeutic selectivity.

Conclusion

AOD-9604 exemplifies the promise and challenges of fragment peptide therapeutics. While its clinical development was ultimately discontinued, the peptide established proof-of-concept for selective lipolytic activity without growth hormone receptor engagement, and continues to inform fragment-based drug discovery programs targeting metabolic and musculoskeletal disorders.